Loading organizations...
Based in Brooklyn, New York, Auxilius develops financial planning, analysis, and accounting software designed to automate clinical trial management and manufacturing processes for the biopharma industry. The B2B software platform enables clinical-stage life sciences organizations to control research and development costs, streamline trial accruals, mitigate financial risk, and optimize long-term forecasting. The enterprise has secured $20 million in total venture funding and currently serves a client base of over 50 biotechnology customers, including pilot programs with major pharmaceutical corporations. Operating with a workforce of over 30 employees, the organization achieved an 800 percent revenue growth rate during the 2023 fiscal year while maintaining revenue under $5 million. Auxilius is backed by a syndicate of venture capital firms, including SignalFire, Renegade Partners, Bain Capital Ventures, and XYZ Venture Capital. The financial technology company was founded in 2020 by Adam Weisman.
Auxilius has raised $20.0M across 2 funding rounds.
Auxilius has raised $20.0M in total across 2 funding rounds.
Auxilius is a Series A SaaS company founded in 2020 that provides R&D financial management software for the biopharma industry, specializing in automating budgeting, planning, forecasting, accruals, and clinical trial financial management (CTFM).[1][2][3][4] Its platform integrates clinical data, invoices, and vendor estimates to replace error-prone spreadsheets, enabling finance, accounting, and clinical operations teams to manage biopharma's largest and most variable costs—clinical trials and CMC—with improved accuracy, audit readiness, and efficiency.[1][2][5] Serving over 50 biotech and pharmaceutical companies, Auxilius achieved 800% year-over-year ARR growth in 2023 and raised $10 million in additional financing led by SignalFire, demonstrating strong growth momentum in a high-stakes sector.[1][3]
Auxilius was founded in 2020 in New York by CEO and co-founder Adam Weisman and his team, emerging from the need to address inefficiencies in biopharma R&D finance, where clinical trial budgets—often the industry's biggest expense—are managed via cumbersome spreadsheets prone to errors and crashes.[1][3][4] The idea crystallized around creating the first CTFM software to automate workflows for life science finance, accounting, and clinical operations, filling a critical gap in forecasting accuracy and expense management.[1] Early traction built through deep engagement in the life sciences community via conferences and events, leading to partnerships with over 50 biopharma firms and explosive 800% ARR growth in 2023, culminating in a $10 million funding round.[1][3]
Auxilius rides the wave of digital transformation in biopharma R&D, where clinical trials represent the largest, most unpredictable expense amid rising costs and regulatory scrutiny.[1][3] Timing aligns with post-pandemic biotech funding recovery and AI-driven efficiencies, as firms seek tools to extend runway, optimize spending, and accelerate innovation—Auxilius directly tackles spreadsheet chaos that hampers 50+ customers.[1][2] Market forces like SOX compliance demands, audit pressures, and CMC complexity favor its compliant automation, positioning it as a category creator in CTFM.[1][5] By empowering smarter resource allocation, Auxilius influences the ecosystem, enabling faster medical breakthroughs and operational efficiency in a $100B+ clinical trials market.[1]
Auxilius is poised to dominate CTFM as biopharma scales AI-integrated trials and faces tighter budgets, with plans to invest in product innovation and go-to-market expansion.[1][3] Trends like AI-enhanced forecasting and global trial complexity will amplify demand, potentially driving further ARR surges and acquisitions by larger ERP players. Its influence could evolve from niche innovator to industry standard, revolutionizing R&D finance and fueling biotech momentum—much like how it transformed spreadsheets into strategic assets for its growing customer base.[1][5]
Auxilius has raised $20.0M across 2 funding rounds. Most recently, it raised $10.0M Other Equity in June 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 12, 2024 | $10M Venture Round | SignalFire | — | Announced |
| Jun 1, 2022 | $10M Series A | Renegade Partners | AlleyCorp, ALT Capital, Bullpen Capital, C2 Investment, Electric Capital, Founders Fund, G20 Ventures, Khosla Ventures, Mkt1 Capital, Plaid, Ribbit Capital, Scalar Capital, Susa Ventures, Vinyl Capital, Work Bench, XYZ Venture Capital, Derrick LI, Matt Macinnis, Michael MA, Parker Conrad | Announced |
Auxilius has raised $20.0M in total across 2 funding rounds.
Auxilius's investors include SignalFire, Renegade Partners, AlleyCorp, Alt Capital, Bullpen Capital, C2 Investment, Electric Capital, Founders Fund, G20 Ventures, Khosla Ventures, MKT1 Capital, Plaid.